TIGIT和PD-1/PD-L1双重阻断途径在肿瘤免疫治疗中的研究进展  

Research progress on dual blockade of TIGIT and PD-1/PD-L1 pathways in tumor immunotherapy

作　　者：王顺娜 高浏璐 郑晓凤 邢国静 王丽菲 邵慧娟 于晓辉 张久聪 Shunna Wang;Liulu Gao;Xiaofeng Zheng;Guojing Xing;Lifei Wang;Huijuan Shao;Xiaohui Yu;Jiucong Zhang(The First Clinical College of Medicine,Gansu University of Traditional Chinese Medicine,Lanzhou 730000,China;Department of Gastroenterology,The 940th Hospital of Joint Logistic Support Force of PLA,Lanzhou 730050,China;Medical College,Northwest University for Nationalities,Lanzhou 730030,China;Department of Gastroenterology,Second Hospital of Lanzhou University,Lanzhou 730030,China)

机构地区：[1]甘肃中医药大学第一临床医学院,兰州市730000 [2]中国人民解放军联勤保障部队第九四〇医院消化内科 [3]西北民族大学医学部4兰州大学第二医院消化内科

出　　处：《中国肿瘤临床》2023年第21期1124-1129,共6页Chinese Journal of Clinical Oncology

基　　金：第九四〇医院院内科研拔尖项目(编号:2021yxky002)资助。

摘　　要：程序性死亡蛋白-1和程序性死亡蛋白配体-1(programmed death-1/programmed death-ligand 1,PD-1/PD-L1)作为一种抑制T细胞活化的调节性免疫检查点分子,在肿瘤的免疫治疗发挥着重要的作用。近年来,越来越多的靶向治疗药物得到研发,但是单一免疫检查点阻断剂并不能很好的抑制肿瘤的发生,肿瘤逃逸现象时有发生,而靶向药物的联合治疗可作为抑制肿瘤发生发展的重要手段之一。属于1型脊髓灰质炎病毒受体的抑制性受体T细胞免疫球蛋白和免疫受体酪氨酸抑制基序(immunoreceptor tyrosine-based inhibition motif,ITIM)结构域(T cell immunoglobulin and ITIM domain,TIGIT)是近年靶向药物治疗研究的热点,其与PD-1/PD-L1的联合治疗可减少肿瘤逃逸,更有效地抑制肿瘤的发生。因此,本文就TIGIT和PD-1/PD-L1双重阻断途径在肿瘤免疫治疗中的研究进展进行归纳总结,旨在肿瘤免疫治疗提供一定的理论依据。Programmed death-1 and programmed death-ligand 1(PD-1/PD-L1)are regulatory immune checkpoint molecules that inhibit T cell activation and,therefore,play an important role in tumor immunotherapy.In recent years,increasing numbers of targeted therapeutic agents have been developed,but single immune checkpoint blockers cannot completely inhibit tumor occurrence,and tumor escape sporadically occurs.Consequently,combination therapy of targeted drugs is considered a useful method to inhibit tumorigenesis and tumor development.T cell immunoglobulin and immunoreceptor tyrosine-based inhibition motif(ITIM)domain(TIGIT)is an inhibitory type 1 poliovirus receptor that has recently been a hotspot of targeted drug therapy research.It has been shown that the combination therapy of TIGIT plus PD-1/PD-L1 can reduce tumor escape and inhibit tumorigenesis more effectively.Therefore,this review summarizes and discusses the progress on the dual blockade of TIGIT and PD-1/PD-L1 pathways in tumor immunotherapy to provide a theoretical basis for tumor immunotherapy.

关 键 词：TIGIT PD-1/PD-L1 双重阻断 肿瘤免疫治疗 研究进展 

分 类 号：R730.51[医药卫生—肿瘤]